Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Additionally, we found patients with vitamin D from IV supplementation (aHR, 0.13; 95% CI, 0.01 to 1.16, P = 0.066) and higher serum phosphorous level (aHR, 0.73; 95% CI, 0.53 to 1.02, P = 0.068) were prone to have a lower risk of chronic thrombocytopenia (Table 2).

Source: Risk Factors for Chronic Leukopenia and Thrombocytopenia. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Older Age and High Serum Ferritin Levels Associated With the Risk of Chronic Cytopenia in Hemodialysis Patients

Study design awaiting verification · Frontiers in Medicine · 2020

Original publication title

Older Age and High Serum Ferritin Levels Associated With the Risk of Chronic Cytopenia in Hemodialysis Patients

Yu-Ting Lee; Wei-Yu Wang; Chin-Ho Kuo; Ming-Yang Lee; Yin-Che Lu; Chih-Yen Hsiao; Yueh-Han Hsu; Peir-Haur Hung

Copyright © 2020 Lee, Wang, Kuo, Lee, Lu, Hsiao, Hsu and Hung.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Leukopenia or thrombocytopenia is sometimes observed in end-stage renal disease (ESRD) patients, but the association between chronic leukopenia or thrombocytopenia and hemodialysis (HD) is still unclear. We aimed to investigate the incidence of chronic leukopenia or thrombocytopenia in patients with ESRD who received HD and to determine the risk factors of this complication. We retrospectively analyzed ESRD patients treated with HD at Ditmanson Medical Foundation Chia-Yi Christian Hospital in 2018. The risk factors for the occurrence of chronic leukopenia and thrombocytopenia were analyzed by Cox regression models.

Of the 473 patients in our study cohort, 46 (9.7%) patients had a hematologic abnormality, including 18 patients with chronic leukopenia, 18 with chronic thrombocytopenia, and 10 with pancytopenia. Multivariate analysis revealed that patient age ≥60 years at the initiation of dialysis was a significant predictor for both chronic leukopenia [adjusted hazard ratio (aHR), 2.71; 95% confidence interval (CI), 1.06-6.89] and chronic thrombocytopenia (aHR, 2.83; 95% CI, 1.08 to 7.35). Chronic liver disease (aHR, 3.31; 95% CI, 1.27 to 8.61) and serum ferritin levels >800 mg/dl (aHR, 3.29; 95% CI, 1.29 to 8.39) were risk factors for chronic thrombocytopenia.

A trend showed that vitamin D from intravenous supplementation (aHR, 0.13; 95% CI, 0.01 to 1.16, P = 0.066) and serum phosphorous level (aHR, 0.73; 95% CI, 0.53 to 1.02, P = 0.068) may be associated with chronic thrombocytopenia. Our study demonstrated that hematological abnormality was a long-term complication of HD. These results reveal that older patients with HD and high serum ferritin levels are at an elevated risk for chronic cytopenia. Healthcare professionals should be aware of this risk when treating HD patients in order to improve their prognosis.

Authors’ abstract

Leukopenia or thrombocytopenia is sometimes observed in end-stage renal disease (ESRD) patients, but the association between chronic leukopenia or thrombocytopenia and hemodialysis (HD) is still unclear. We aimed to investigate the incidence of chronic leukopenia or thrombocytopenia in patients with ESRD who received HD and to determine the risk factors of this complication. We retrospectively analyzed ESRD patients treated with HD at Ditmanson Medical Foundation Chia-Yi Christian Hospital in 2018. The risk factors for the occurrence of chronic leukopenia and thrombocytopenia were analyzed by Cox regression models.

Of the 473 patients in our study cohort, 46 (9.7%) patients had a hematologic abnormality, including 18 patients with chronic leukopenia, 18 with chronic thrombocytopenia, and 10 with pancytopenia. Multivariate analysis revealed that patient age ≥60 years at the initiation of dialysis was a significant predictor for both chronic leukopenia [adjusted hazard ratio (aHR), 2.71; 95% confidence interval (CI), 1.06-6.89] and chronic thrombocytopenia (aHR, 2.83; 95% CI, 1.08 to 7.35). Chronic liver disease (aHR, 3.31; 95% CI, 1.27 to 8.61) and serum ferritin levels >800 mg/dl (aHR, 3.29; 95% CI, 1.29 to 8.39) were risk factors for chronic thrombocytopenia.

A trend showed that vitamin D from intravenous supplementation (aHR, 0.13; 95% CI, 0.01 to 1.16, P = 0.066) and serum phosphorous level (aHR, 0.73; 95% CI, 0.53 to 1.02, P = 0.068) may be associated with chronic thrombocytopenia. Our study demonstrated that hematological abnormality was a long-term complication of HD. These results reveal that older patients with HD and high serum ferritin levels are at an elevated risk for chronic cytopenia. Healthcare professionals should be aware of this risk when treating HD patients in order to improve their prognosis.

Publication and source details

Original title: Older Age and High Serum Ferritin Levels Associated With the Risk of Chronic Cytopenia in Hemodialysis Patients

Yu-Ting Lee; Wei-Yu Wang; Chin-Ho Kuo; Ming-Yang Lee; Yin-Che Lu; Chih-Yen Hsiao; Yueh-Han Hsu; Peir-Haur Hung

Frontiers in Medicine · 2020

Edited by: Natalia Lopez-Andres, NavarraBiomed, Spain

Reviewed by: Maria-Eleni Roumelioti, University of New Mexico, United States; Ashish K. Solanki, Medical University of South Carolina, United States

*Correspondence: Peir-Haur Hung dtmedg3@yahoo.com.tw

This article was submitted to Nephrology, a section of the journal Frontiers in Medicine

†These authors have contributed equally to this work

Copyright © 2020 Lee, Wang, Kuo, Lee, Lu, Hsiao, Hsu and Hung.2020Lee, Wang, Kuo, Lee, Lu, Hsiao, Hsu and Hunghttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T15:33:38.691727+00:00

DOI: 10.3389/fmed.2020.568350 · PMC7662880